Biorestorative Therapies, Inc. (BRTX) vs Virax Biolabs Group Limited (VRAX)

Biorestorative Therapies, Inc. and Virax Biolabs Group Limited are both Biotechnology companies. Biorestorative Therapies, Inc. and Virax Biolabs Group Limited are of similar size ($3.5M and $3.3M). Virax Biolabs Group Limited has the higher net margin (0.00% vs −3,089.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Virax Biolabs Group Limited leads on 8 and Biorestorative Therapies, Inc. on 4.

Valuation

Metric BRTX VRAX Biotechnology median
P/E n/m n/m 7.88
P/S 6.32 n/m 11.47
P/B 0.75 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.09 0.86 0.74
EV/Sales (3.60) n/m 10.73
Earnings yield (839.22%) (222.08%) (28.84%)
Free cash flow yield (579.97%) 0.00% (23.03%)

Profitability

Metric BRTX VRAX Biotechnology median
Gross margin 92.09% — 65.16%
Operating margin (3,974.66%) — 0.00%
Net margin (3,089.30%) 0.00% 0.00%
Free cash flow margin (3,302.04%) 0.00% 0.00%
Return on equity (241.50%) 0.00% (57.72%)
Return on assets (147.75%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BRTX VRAX Biotechnology median
Revenue growth (TTM) (8.47%) — 5.64%
EPS growth (last fiscal year) (36.21%) 68.79% —
Revenue growth, 5-year CAGR 36.11% (36.88%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BRTX VRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.35 9.97 4.73
Net debt to EBITDA 0.19 1.08 0.96

Dividend

Metric BRTX VRAX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric BRTX VRAX Biotechnology median
Market cap 3.47m 3.28m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack